🇹🇷 Türkçe

Schizophrenia (SCZ)

Definition

Schizophrenia is a severe, chronic psychiatric disorder defined by three symptom domains: positive symptoms, negative symptoms, and cognitive impairments. Diagnosed per DSM-5 / ICD-11 criteria requiring characteristic symptoms for ≥6 months with active-phase symptoms for ≥1 month.

Symptoms

Positive symptoms:

  • Delusions
  • Hallucinations (most commonly auditory)
  • Disorganized thought and speech
  • Disorganized or catatonic behavior

Negative symptoms:

  • Social withdrawal and flat affect
  • Alogia (poverty of speech)
  • Avolition (lack of motivation)
  • Anhedonia

Cognitive impairments:

  • Working memory deficits
  • Impaired executive function
  • Processing speed reduction

Heritability and Etiology

SCZ is highly heritable (~80%), but twin discordance and environmental factors indicate non-genetic contributions. A complex, polygenic risk architecture underlies most cases. Developmental abnormalities (neuronal migration, GABAergic circuitry) are implicated.

Integrated Sociodevelopmental-Cognitive Model

A leading framework (Howes & Murray, 2014) proposes that SCZ results from the integration of three main factors:

  1. Developmental Sensitization: Genetic risk (e.g., DISC1, NRG1) and early hazards (obstetric complications, childhood adversity) sensitize the dopamine system.
  2. Social Adversity: Stressors like migration, urbanicity, and social defeat bias cognitive schemas toward paranoid interpretations.
  3. The Vicious Cycle: Acute stress triggers dysregulated, excessive presynaptic dopamine release (high synthesis capacity). This leads to aberrant salience—attributing importance to neutral stimuli—which the biased cognitive schema then misinterprets as psychotic experiences (e.g., delusions). The resulting paranoia increases stress, further dysregulating dopamine and “hard-wiring” the beliefs.

Dopamine Hypothesis: Presynaptic Shift

While traditionally focused on postsynaptic D2 receptor hypersensitivity (the target of antipsychotics), modern evidence (meta-analysis of >50 PET/SPECT studies) indicates that the primary locus of dysfunction is presynaptic:

  • Elevated DA synthesis capacity: Specifically seen in the striatum of individuals with frank psychosis.
  • Increased DA release: Triggered by stress, amphetamine challenge, or cortical glutamatergic disinhibition.
  • Dynamic Nature: DA dysregulation is not static but fluctuates, increasing during the progression from prodrome to the first psychotic episode.

Glutamate-Dopamine Interaction

Modern evidence (McCutcheon et al., 2020) suggests that schizophrenia is not just a dopamine disorder but involves a complex interplay between glutamatergic and dopaminergic systems:

  • NMDA Hypofunction: Reduced function of NMDA glutamate receptors, particularly on GABAergic interneurons in the prefrontal cortex and hippocampus, leads to a disinhibition of glutamatergic pyramidal neurons.
  • Circuit Disruption: These overactive glutamatergic neurons then over-stimulate midbrain dopamine neurons, causing the excessive presynaptic dopamine release observed in the striatum.
  • Transmitter Mapping: While striatal dopamine is primarily associated with positive symptoms (hallucinations, delusions), cortical glutamatergic deficits are more closely linked to cognitive and negative symptoms.
  • Treatment Resistance: Patients who do not respond to traditional D2-blocking antipsychotics often show higher levels of cortical glutamate, suggesting a primary glutamatergic pathology in treatment-resistant cases.

Epigenetic Mechanisms

  • RELN hypermethylation in PFC: Reelin promoter is hypermethylated in SCZ brain, reducing reelin expression. Reelin controls neuronal migration; deficiency may drive developmental abnormalities. Associated with elevated DNMT1. Unrelated to antipsychotic drug exposure. (Established: postmortem human brain; replicated.)
  • SOX10 hypermethylation: Transcription factor important in oligodendrocyte development; hypermethylation → reduced expression → myelin abnormalities. (Established: postmortem; polymorphisms in SOX10 also affect age of SCZ onset.)
  • GAD1 epigenetic dysregulation: GAD1 encodes glutamic acid decarboxylase-1 (key GABA synthesis enzyme). In PFC, shows excessive repressive DNA and histone methylation, reduced H3K4me3 (activation mark), and weakened 3D enhancer-promoter looping. GABAergic transmission impairment in PFC confirmed by in vivo neuroimaging. (Robust: multiple labs, multiple methods.)
  • 3D chromatin architecture: Chromosomal loop formations at GAD1 and CACNA1C are disrupted in SCZ PFC. (Emerging; importance of noncoding risk variants may be explained by this.)
  • HLA gene methylation changes: Aberrant methylation of HLA genes in PFC — implicates neuroinflammation in pathogenesis. (Preliminary.)
  • HMT upregulation: Increased levels of several histone methyltransferases in SCZ brain. (Postmortem finding; functional implications unclear.)
  • Chromatin regulator mutations: ~50 genes encoding chromatin regulators linked to neurodevelopmental syndromes including rare monogenic SCZ forms (e.g., KMT1D, KMT2F, ZNF804A duplications). (Established for rare forms.)

GABAergic Hypothesis

A consistent finding across epigenetic, transcriptomic, and now in vivo neuroimaging studies is impaired GABAergic transmission in PFC of SCZ patients, especially at interneurons expressing GAD1/GAD67. This is among the best-supported mechanistic hypotheses in SCZ. (See: Epigenetic Regulation)

Treatment Response Note

All available antipsychotics antagonize (or partially agonize) D2 dopamine receptors. They improve positive symptoms but show far less efficacy for negative symptoms and cognitive impairments. Most patients show incomplete response. No treatment directly targets epigenetic mechanisms in current clinical practice.